News
KTE-C19 feasible in most young, high-risk ALL patients, study suggests
Photo by Bill Branson SAN DIEGO—Trial results suggest treatment with the chimeric antigen receptor (CAR) T-cell therapy KTE-C19 is feasible for...
News
G-CHOP no better than R-CHOP in previously untreated DLBCL
SAN DIEGO—Substituting obinutuzumab for rituximab in combination with CHOP chemotherapy does not improve outcomes in patients with previously...
News
MPNs limit daily activities and ability to work
2016 ASH Annual Meeting SAN DIEGO—Many patients living with myeloproliferative neoplasms (MPNs) have a high burden of disease that affects their...
News
Half of CML patients can stop TKI therapy, study suggests
© Todd Buchanan 2016 SAN DIEGO—Updated results of the EURO-SKI trial support the idea that certain chronic myeloid leukemia (CML) patients can...
News
Combo shows early promise in newly diagnosed AML
© Todd Buchanan 2016 SAN DIEGO—A targeted therapy combined with standard chemotherapy can produce rapid, deep remissions in patients with newly...
News
Better ways to drive CAR T-cell therapy
© ASCO/Brian Powers CHICAGO—Treatment dose and schedule, as well as a patient’s tumor burden, influence the outcome of therapy with chimeric...
News
Lenalidomide maintenance after transplant improves OS in MM
the ASCO Annual Meeting © ASCO/Todd Buchanan CHICAGO—Lenalidomide maintenance after high-dose melphalan and autologous stem cell transplant (ASCT...
News
Most CML patients who stop nilotinib stay in remission
CHICAGO—Nearly 60% of chronic myeloid leukemia (CML) patients who switch to nilotinib from imatinib maintain treatment-free remission for 48 weeks...
News
Combo deepens responses and improves PFS in MM
Photo courtesy of the University of Navarra ORLANDO, FL—The addition of panobinostat to bortezomib-dexamethasone therapy in relapsed or...
News
CAR T cells persist for 3 years in young ALL patients
Photo courtesy of Penn Medicine ORLANDO, FL—CTL019, a CD19 chimeric antigen receptor (CAR) T-cell therapy, can persist for 3 years or longer in...
News
Five-year data suggest ruxolitinib improves survival in MF
ASH Annual Meeting Photo courtesy of ASH ORLANDO, FL—Five-year results from the COMFORT-II trial appear to confirm that treatment with...
News
Panobinostat combos can treat rel/ref MM
©ASCO/Rodney White CHICAGO—Combination regimens including the histone deacetylase inhibitor panobinostat can produce durable responses and...
News
CAR T-cell therapy seems feasible for NHL, MM
©ASCO/Rodney White CHICAGO—The CD19-directed chimeric antigen receptor (CAR) T-cell therapy CTL019 has shown promise for treating non-Hodgkin...
News
Iron chelation improves survival in lower-risk MDS
Photo courtesy of ASH SAN FRANCISCO—Iron chelation therapy significantly improves survival for patients with lower-risk myelodysplastic syndrome...
News
Product controls bleeding in kids with hemophilia A
the 2014 ASH Annual Meeting SAN FRANCISCO—A recombinant factor VIII (FVIII) Fc fusion protein is effective for routine prophylaxis and control of...